Trial Profile
Single-center, open-label, phase I study to investigate the pharmacokinetics (PK), tolerability, and safety of a single oral dose of macitentan in subjects with severe renal function impairment.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Aug 2014
Price :
$35
*
At a glance
- Drugs Macitentan (Primary)
- Indications Eisenmenger complex; Glioblastoma; Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension; Skin ulcer
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 14 Aug 2014 New trial record